Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Am J Psychiatry. 2016 Mar 4;173(6):588–599. doi: 10.1176/appi.ajp.2015.15070907

Table 5.

Cannabis-Specific Treatment/intervention Among Individuals with 12-Month and Lifetime Cannabis Use Disorder

Treatment/intervention Setting 12-Month Cannabis Use Disorder Lifetime Cannabis Use Disorder
Any % (se) Mild% (se) Moderate% (se) Severe% (se) Any % (se) Mild% (se) Moderate% (se) Severe% (se)
12-Step program 3.17 (0.79) 1.07 (0.45) 3.79 (1.79) 7.63 (2.90) 7.98 (0.71) 3.64 (0.64) 7.10 (1.45) 14.81 (1.69)
Family/social services 0.86 (0.35) 0.78 (0.48) 0.36 (0.36) 1.57 (1.05) 1.96 (0.39) 0.85 (0.31) 1.44 (0.61) 3.92 (0.98)
Detoxification 1.04 (0.55) 0.27 (0.27) 0.15 (0.15) 3.80 (2.30) 2.66 (0.42) 1.00 (0.33) 1.87 (0.73) 5.58 (1.05)
Other inpatient facility 1.16 (0.55) 0.12 (0.12) 0.70 (0.56) 4.16 (2.32) 1.62 (0.32) 0.36 (0.17) 1.33 (0.50) 3.62 (0.92)
Outpatient clinic 1.46 (0.56) 0.39 (0.29) 0.71 (0.50) 4.81 (2.31) 3.98 (0.64) 1.11 (0.43) 3.09 (1.04) 8.73 (1.33)
Rehabilitation program 1.51 (0.59) 0.54 (0.39) 0.68 (0.47) 4.70 (2.37) 4.98 (0.56) 2.17 (0.55) 4.53 (1.19) 9.32 (1.30)
Methadone maintenance - - - - 0.02 (0.01) - - 0.06 (0.05)
Emergency department 0.04 (0.04) - - - 0.77 (0.21) 0.35 (0.21) 0.47 (0.35) 1.59 (0.54)
Halfway house 0.06 (0.06) - - - 0.58 (0.15) 0.15 (0.13) 0.11 (0.11) 1.52 (0.44)
Crisis center 0.23 (0.17) - - - 0.63 (0.20) 0.25 (0.16) 0.19 (0.16) 1.49 (0.54)
Employee assistance program - - - - 0.60 (0.19) 0.56 (0.29) 0.28 (0.28) 0.89 (0.39)
Clergy 0.70 (0.30) - 0.88 (0.64) 2.21(1.16) 1.46 (0.27) 0.52 (0.28) 1.71 (0.61) 2.63 (0.60)
Physician/other health carepractitioners 4.83 (1.24) 2.96 (1.53) 3.73 (2.42) 10.50 (2.80) 5.18 (0.59) 2.78 (0.84) 4.67 (1.38) 8.96 (1.11)
Other 0.64 (0.34) 0.10 (0.10) - 2.63 (1.47) 1.04 (0.26) 0.66 (0.25) 0.45 (0.27) 1.98 (0.71)
Any treatment or intervention 7.16 (1.35) 4.14 (1.62) 5.98 (2.49) 15.73 (3.49) 13.69 (0.86) 7.26 (0.90) 11.72 (1.86) 24.27 (1.91)

Note: -, Zero prevalence.